

# Efficacy of the Oral Plasma Kallikrein Inhibitor Sebetralstat (KVD900) by Attack Location in a Phase 2 Clinical Trial in Patients With Hereditary Angioedema

<sup>1</sup>University Hospital Frankfurt, Frankfurt, Frankfurt, Germany; <sup>2</sup>ASST Fatebenefratelli Sacco, Ospedale Luigi Sacco-University of Milan, Italy; <sup>3</sup>Amsterdam, Netherlands; <sup>4</sup>KalVista Pharmaceuticals, Salisbury, UK, and Cambridge, MA, US; <sup>5</sup>Veramed Limited, Twickenham, UK

# Background injection-site-associated pain and discomfort<sup>8-11</sup> Methods





# Acknowledgments

Medical writing assistance was provided under the direction of the authors by Katherine Stevens-Favorite, PhD, of Cadent, a Syneos Health group company, and was supported by KalVista Pharmaceuticals, Inc.

# Emel Aygören-Pürsün,<sup>1</sup> Andrea Zanichelli,<sup>2</sup> Danny M. Cohn,<sup>3</sup> Paul K. Audhya,<sup>4</sup> Peter Williams,<sup>5</sup> Chris M. Yea,<sup>4</sup> Michael D. Smith<sup>4</sup>

# 

- 6. Maurer M, et al. *Allergy*. 2018;73(8):1575-1596.

- 14. Riedl M, et al. Ann Allergy Asthma Immunol. 2010;105(6):430-436.e2.